Phase 1/2 trial

August 9, 2019September 10, 2019

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

News

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking ... Read more

March 1, 2019

UPMC Trial to Explore Ampligen Combo for Recurrent Ovarian Cancer

News

A new investigator-sponsored clinical trial is recruiting women with recurrent, platinum-sensitive ovarian cancer to study a combination of Hemispherx Biopharma’s investigational product Ampligen (rintatolimod) plus chemo-immunotherapy, the company announced. The Phase 1/2 trial ... Read more

July 20, 2018

Phase 1/2 Trial Begins on ONCOS-102, Imfinzi Combination in Advanced Ovarian, Colorectal Cancers

News

A new Phase 1/2 clinical trial has been launched testing a combination of investigational viral therapy ONCOS-102 and Imfinzi (durvalumab) in patients with advanced ovarian and colorectal cancers. The open-label trial ... Read more

July 6, 2018

Basilea Begins Phase 2a Expansion Trial Testing BAL101553 in Ovarian, Brain Cancers

News

Basilea Pharmaceutica has dosed its first patient in the expansion part of its Phase 1/2 trial (NCT02895360), which continues to explore the safety and effectiveness of BAL101553, an investigational tumor checkpoint controller, ... Read more

April 9, 2018

Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial

News

A combination of Zejula (niraparib) and Keytruda (pembrolizumab) reduced tumor size in one out of four difficult-to-treat ovarian cancer patients, Tesaro‘s Phase 1/2 trial revealed. The 25% response rate seen in ... Read more

October 18, 2017

Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors

News

The investigational medicine tinostamustine (EDO-S101), developed by Mundipharma EDO GmbH, is now being tested in patients with advanced solid tumors, including ovarian cancer, in a first-in-human Phase 1/2 clinical trial. ... Read more

September 22, 2017September 22, 2017

DelMar Announces VAL-083 Clinical Trials Will Soon Start for Recurrent Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved DelMar Pharmaceuticals’ investigational new drug (IND) application for VAL-083 for the treatment of ovarian cancer. The IND approval allows the company ... Read more